U.S. FDA approves Celgene's Abraxane for pancreatic cancer
Sept 6 (Reuters) - Celgene Corp's drug Abraxane was approved as a treatment for pancreatic cancer by the U.S. Food and Drug Administration on Friday.
Abraxane is currently approved to treat breast cancer and non-small cell lung cancer. In a clinical trial, patients with pancreatic cancer who received Abraxane plus the chemotherapy gemcitabine lived, on average, 1.8 months longer than those who received gemcitabine alone.
- Islamic State threat 'beyond anything we've seen': Pentagon
- British Muslims blame jihadi subculture after beheading video |
- Israeli air strike kills three Hamas commanders in Gaza |
- U.S. aid workers who survived Ebola leave Atlanta hospital |
- National Guard to withdraw from riot-torn Ferguson, Missouri |